PR Newswire RIO DE JANEIRO, Sept. 27, 2024 45 percent reduction in risk of death achieved with CARVYKTI® after three-year follow-up in landmark CARTITUDE-4 study Data featured in a late-breaking oral presentation at the 2024 ...
PR Newswire SAN DIEGO, Sept. 27, 2024 Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or ...
PR Newswire NORTH CHICAGO, Ill., Sept. 27, 2024 - Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression. - ...
PR Newswire TAIPEI, Sept. 27, 2024 TAIPEI, Sept. 27, 2024 /PRNewswire/ -- Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's ...
PR Newswire SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 27, 2024 SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 27, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to ...
PR Newswire CHICAGO, Sept. 26, 2024 CHICAGO, Sept. 26, 2024 /PRNewswire/ -- In the past decade, clinical trials have contributed to rapidly advancing research, which has led to more individuals living with lung cancer exceeding the five-year ...
PR Newswire BURR RIDGE, Ill., Sept. 26, 2024 BURR RIDGE, Ill., Sept. 26, 2024 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided ...
PR Newswire NEW YORK, Sept. 26, 2024 NEW YORK, Sept. 26, 2024 /PRNewswire/ -- More than a dozen bacterial species among the hundreds that live in people's mouths have been linked to a collective 50% increased chance of developing head and ...
PR Newswire ATLANTA, Sept. 26, 2024 Crucial Catch funds support increasing access to low or no cost cancer screenings in all NFL markets across the country ATLANTA, Sept. 26, 2024 /PRNewswire/ -- Through Crucial Catch, the American ...
PR Newswire MANASQUAN, N.J., Sept. 26, 2024 20% Of Sales This Weekend Support Research to Prevent and Cure Breast Cancer MANASQUAN, N.J., Sept. 26, 2024 /PRNewswire/ -- Jersey Mike's Subs is teaming up with the Breast Cancer Research ...
New research has developed an immunotherapy for cancer by combining DNase I with CAR T-cell therapy. The research conducted by Xenetic Biosciences titled, "The synergistic action of DNase I and CAR T cells enhances the therapeutic efficacy ...
Anti-EGFR antibody treatment is given to treat patients with metastatic colorectal cancer (CRC). However, due to mutations in the tumor cells, it becomes resistant to the treatment making it less effective ( ). CRC is one of the ...
The term Minimal residual disease (MRD) was first introduced to describe the strong association between MRD detection after treatment and the risk of relapse. MRD is the least amount of cancer cells that remain in the body during or after treatment. The technologies for detecting MRD have evolved along with its potential applications as these technologies are now used for studying MRD in multiple solid tumors. More assays are available even before their clinical use is proven. The assays or tests vary in sensitivity, detection limits and evidence that support their use. Can all Liquid Biopsy Tests Detect MRD? MRD, cell - free DNA(cfDNA) and circulating tumor DNA (ctDNA) are interchangeable under the field of liquid biopsy even though their meanings do not overlap. Their applications are different so it is important to know how they differ. Most current tests detect ctDNA that detects the fraction of cfDNA released by tumor cells. In healthy persons the blood is rich in cfDNA released by dying cells and the ctDNA needs to be deducted from cfDNA. Not all ctDNA tests are MRD detectable tests. MRD tests are highly sensitive and will be able to detect even small traces of ctDNA. But most of the commercially available liquid biopsy tests focus on detecting druggable alteration and tumor features. MRD tests are classified into 2 categories Tumor-informed test : uses archival tumor tissue (tissue embedded in paraffin and stored) to detect tumor specific alteration which is then used to detect MRD in blood. Newer tumor-informed tests can detect thousands of mutations, lowering the limit of detection down to 1 part per million. Tumor-naíve test : blood only tests that use tumor-intrinsic features such as epigenomic profiling and fragment length to identify minimal traces of ctDNA with cfDNA. Tumor-informed tests have the highest sensitivity but their higher cost and longer turnaround times are disadvantages. Can MRD be Used as a Biomarker? Almost all patients who test MRD positive after treatment experience recurrence. MRD can be a powerful prognostic biomarker that can find people with varying cancer risk recurrence. Guiding adjuvant treatment : MRD detection after surgery can be used to personalize adjuvant or post surgery treatment. MRD-positive patients can be treated with targeting residual disease, while MRD-negative patients can avoid the potential toxicity. Adaptive treatment strategies during therapy : MRD clearance during neoadjuvant therapy is viewed as a supplement for treatment response. Researchers are exploring whether MRD status can help mid-treatment adjustments to improve therapy outcome. Recurrence prevention : MRD monitoring during follow up offers advantage over traditional tumor markers by detecting recurrence rate. But it is not clear if early intervention based on this can alter the natural course of disease or if it is an advanced diagnostic sensitivity without changing outcomes. Ultimately, as MRD assays become more advanced and data from ongoing trials become available, MRD has the potential to redefine treatment paradigms, offering more personalized and effective approaches across cancer types. Reference: NCCN Issues Updated Guidance on Genetic Testing for Several Cancers - (https:...
A new study reveals a key mechanism driving skin cancer. Researchers have identified a protein-ion channel interaction that fuels tumor growth. ( ) What is Melanoma Melanoma arising from pigment-producing cells known as melanocytes is the deadliest form of skin ...
While the Centers for Disease Control and Prevention (CDC) advises that reducing alcohol consumption or abstaining can lower cancer risk, data from the Annenberg Public Policy Center (APPC) reveal that fewer than half of Americans are aware that regular alcohol consumption increases the risk of developing cancer later in life. ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers